R&D News | pharmaphorum

News

Gilead grabs full rights to Jounce cancer immunotherapy

Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th

News

FDA slaps partial hold on Biogen, InnoCare MS drug

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year f

News

Merck puts big bucks behind ADC alliance with China's Kelun

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech tha

News

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the

News

UK, Moderna formalise 10-year vaccines alliance

Construction will start early next year on a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance betwee

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

Gilead grabs full rights to Jounce cancer immunotherapy

FDA slaps partial hold on Biogen, InnoCare MS drug

Merck puts big bucks behind ADC alliance with China's Kelun

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

UK, Moderna formalise 10-year vaccines alliance

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks